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Abstract
Objective:  Clarify  the  frequency  and  the  pathophysiological  mechanisms  of  the  rare  manifes-
tations of  Epstein--Barr  virus  infection.
Sources:  Original  research  studies  published  in  English  between  1985  and  2015  were  selected
through a  computer-assisted  literature  search  (PubMed  and  Scopus).  Computer  searches  used
combinations  of  key  words  relating  to  ‘‘EBV  infections’’  and  ‘‘atypical  manifestation.’’
Summary  of  the  ﬁndings:  Epstein--Barr  virus  is  a  herpes  virus  responsible  for  a  lifelong  latent
infection  in  almost  every  adult.  The  primary  infection  concerns  mostly  children  and  presents
with the  clinical  syndrome  of  infectious  mononucleosis.  However,  Epstein--Barr  virus  infection
may exhibit  numerous  rare,  atypical  and  threatening  manifestations.  It  may  cause  secondary
infections and  various  complications  of  the  respiratory,  cardiovascular,  genitourinary,  gastroin-
testinal, and  nervous  systems.  Epstein--Barr  virus  also  plays  a  signiﬁcant  role  in  pathogenesis  of
autoimmune  diseases,  allergies,  and  neoplasms,  with  Burkitt  lymphoma  as  the  main  representa-
tive of  the  latter.  The  mechanisms  of  these  manifestations  are  still  unresolved.  Therefore,  the
main suggestions  are  direct  viral  invasion  and  chronic  immune  response  due  to  the  reactivation
of the  latent  state  of  the  virus,  or  even  various  DNA  mutations.
Conclusions:  Physicians  should  be  cautious  about  uncommon  presentations  of  the  viral  infection
and consider  EBV  as  a  causative  agent  when  they  encounter  similar  clinical  pictures.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.PALAVRAS-CHAVE
Vírus  de
Epstein--Barr;
Mononucleose
infecciosa;
Manifestac¸ões  atípicas  do  vírus  de  Epstein--Barr  em  crianc¸as:  um  desaﬁo  diagnóstico
Resumo
Objetivo:  Esclarecimento  da  frequência  e  dos  mecanismos  patoﬁsiológicos  das  manifestac¸ões
raras da  infecc¸ão  por  vírus  de  Epstein--Barr.
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Crianc¸as;
Complicac¸ões
Fontes:  Estudos  de  pesquisas  originais  publicados  em  inglês  entre  1985  e  2015  foram  seleciona-
dos por  meio  de  uma  busca  na  literatura  assistida  por  computador  (Pubmed  e  Scopus).  As  buscas
no computador  utilizaram  combinac¸ões  de  palavras-chave  relacionadas  a  ‘‘infecc¸ões  por  VEB’’
e ‘‘manifestac¸ão  atípica’’.
Resumo  dos  achados:  O  vírus  de  Epstein--Barr  é  um  herpesvírus  responsável  por  uma  infecc¸ão
latente vitalícia  em  quase  todo  adulto.  A  infecc¸ão  primária  ocorre  principalmente  em  crianc¸as  e
se apresenta  como  síndrome  clínica  da  mononucleose  infecciosa.  Contudo,  a  infecc¸ão  por  vírus
de Epstein--Barr  pode  apresentar  diversas  manifestac¸ões  raras,  atípicas  e  de  alto  risco.  Ela  pode
causar infecc¸ões  secundárias  e  diversas  complicac¸ões  dos  sistemas  respiratório,  cardiovascular,
geniturinário,  gastrointestinal  e  nervoso.  O  vírus  de  Epstein--Barr  também  desempenha  um
papel signiﬁcativo  na  patogênese  de  doenc¸as,  alergias  e  neoplasias  autoimunes,  com  o  linfoma
de Burkitt  sendo  o  principal  representante  das  últimas.  Os  mecanismos  dessas  manifestac¸ões
ainda não  foram  resolvidos.  Portanto,  as  principais  sugestões  são  invasão  viral  direta  e  resposta
imune crônica  devido  à  reativac¸ão  do  estado  latente  do  vírus  ou  mesmo  diversas  mutac¸ões  do
DNA.
Conclusões: Os  médicos  devem  tomar  cuidado  sobre  apresentac¸ões  incomuns  de  infecc¸ão  viral
e considerar  o  VEB  um  agente  causador  quando  encontrarem  situac¸ões  clínicas  semelhantes.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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pstein--Barr  virus  (EBV)  is  a  common  infectious  agent,  found
n  approximately  95%  of  the  world’s  population.  Primary
nfection  with  EBV  is  more  frequent  during  childhood  and
auses  a  mild  infection,  which  usually  presents  with  no
ymptoms.1 However,  when  primary  infection  occurs  dur-
ng  adolescence,  it  leads  to  infectious  mononucleosis  (IM)
n  30--70%  of  cases,  where  up  to  20%  of  B  lymphocytes  are
nfected  with  EBV.1,2
EBV  is  a  DNA  virus  belonging  to  the  herpes  family,  and  is
lso  known  as  human  herpes  virus  4.  It  is  composed  of  a  lin-
ar  dsDNA  genome  enclosed  by  a  capsid,  which  is  surrounded
y  the  tegument  and  a  host  cell  membrane-derived  envelope
mbedded  with  glycoproteins.  EBV  has  a  large  genome,  cod-
ng  for  87  proteins.  The  functions  of  72  of  these  proteins
ave  been  deﬁned  so  far.1
EBV  transmission  is  achieved  with  saliva  it  and  initially
nfects  epithelial  cells  in  the  oropharynx  and  nasopharynx.
fterwards,  EBV  enters  the  underlying  tissues  and  infects
-cells.  After  a  primary  lytic  infection,  EBV  is  capable  of
emaining  dormant  in  resting  memory  B-cells,  from  which  it
eriodically  reactivates.  The  ability  of  reactivation  makes
BV  a  constant  challenge  to  the  host.1
IM  is  the  main  clinical  entity  caused  by  EBV.  Diagnosis
s  based  on  clinical  examination,  revealing  the  classic  triad
f  fever,  lymphadenopathy,  and  pharyngitis,3 and  laboratory
ndings  including  the  presence  of  atypical  lymphocyto-
is  and  heterophile  antibodies.2 The  disease  is  managed
peciﬁcally  with  supportive  care,  since  it  is  a  self-limited
nfection.3 However,  IM  has  been  associated  with  numerous
arly  or  late  complications,  with  a  range  of  graveness.This  review  focuses  on  the  rare  manifestations  of  IM
n  children.  Original  research  studies  published  in  English
etween  1985  and  2015  were  selected  through  a  computer-
ssisted  literature  search  (PubMed  and  Scopus).  Computer
U
U
cearches  used  combinations  of  key  words  relating  to  ‘‘EBV
nfections’’  and  ‘‘atypical  manifestation.’’  In addition,  the
eference  lists  of  the  retrieved  articles  helped  in  the  search
or  other  relevant  articles,  which  were  not  found  during  the
earching  procedure.  Thus,  48  studies  were  selected  and  dis-
ussed  here  (24  case  reports,  14  reviews,  ﬁve  case  control
tudies,  one  population-based  study,  two  letters  to  editor,
ne  cohort  study,  one  meta-analysis).  The  potential  factors,
hich  may  bias  the  ﬁndings  of  this  review,  are  restriction  of
rticles  to  English,  together  with  database  and  citation  bias.
econdary infections
cute  dacryocystitis
cute  dacryocystitis  is  a  rare  complication  of  IM,  with  only
ve  reported  cases.  It  is  deﬁned  by  a  painful,  palpable  mass
n  the  medial  canthal  area,  usually  accompanied  by  fever.4
The  etiology  is  nasal  epithelial  edema  and  lymphoid
yperplasia  from  IM,  which  cause  temporary  nasolacrimal
uct  obstruction.  Colonization  of  lacrimal  saccontents  by
espiratory  pathogens  ultimately  leads  to  acute  dacryocys-
itis.  This  complication  is  likely  to  occur  in  children  and
oung  adults  due  to  the  smaller  nasal  anatomy  and  unique
pidemiology  of  EBV.4
Patients  with  IM  and  acute  dacryocystitis  should  be
reated  with  antibiotics;  drainage  of  the  lacrimal  sac  abscess
ay  be  required.4
espiratory complicationspper  airway  obstruction
pper  airway  obstruction  is  a  conceivably  life  threatening
omplication  of  IM.  Signiﬁcant  airway  obstruction  affects
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AAtypical  manifestations  of  Epstein--Barr  virus  in  children  
approximately  1--3.5%  of  cases.  Suspicion  should  be  raised
in  the  presence  of  odynophagia,  cervical  lymphadenopathy,
and  symptoms  of  respiratory  distress.5
IM  causes  inﬂammation  of  Waldeyer’s  ring,  edema  of
the  pharynx  and  epiglottis,  and  pseudomembrane  forma-
tion  in  the  large  airways.  Signs  of  severe  upper  airway
obstruction  are  often  absent  during  the  ﬁrst  stages  of  the
disease.  Patients  should  be  treated  with  corticosteroids,  and
in  severe  cases,  acute  tonsillectomy,  endotracheal  intuba-
tion,  or  tracheotomy  may  be  mandatory  in  order  to  secure
the  airway.5
Pneumonia
Pulmonary  involvement  is  found  in  5--10%  of  the  IM  cases
in  children.  Reports  of  severe  EBV  symptomatic  lung  infec-
tion  are  rare  and  frequently  described  in  immunosuppressed
adults.  There  have  been  ﬁve  reported  cases  of  severe  lung
involvement  in  EBV  infection  in  children.  Three  of  these
children  suffered  from  respiratory  distress  and  interstitial
pneumonitis,  one  from  bilateral  lower  lobe  consolidation
and  effusion  complicated  by  hemoptysis,  and  the  last  one
from  pleuropneumonia.6
The  pathophysiological  mechanism  includes  lymphocytes
infected  by  EBV,  which  inﬁltrate  the  lung  during  acute  IM.
However,  it  is  questionable  whether  this  pulmonary  involve-
ment  is  the  result  of  direct  viral  invasion  of  lung  or  whether
it  represents  an  immunologic  reaction  to  the  virus.  It  has  also
been  suggested  that  EBV  acts  as  a  co-pathogen  or  induces
ax  temporary  immunosuppression,  causing  susceptibility  to
another  infection.6
Cardiovascular complications
Acute  myocarditis
Prevalence  of  EBV  is  estimated  to  be  less  than  1%  in  viral
myocarditis,3 while  there  are  several  anecdotal  reports  of
heart  complications  from  IM  during  the  last  60  years.7 EBV
and  CMV  are  associated  with  this  pathology,  particularly
after  heart  transplantation.8
The  pathophysiological  progression  is  composed  of  three
phases.  During  the  ﬁrst  phase,  destruction  of  the  car-
diomyocytes  derives  directly  from  virus-mediated  lysis  or
indirectly  from  immune  response  with  the  expression  of
proinﬂammatory  cytokines.  During  the  second  phase,  T-cells
detect  the  viral  antigen  and  destroy  the  infected  cardiac
cells  through  cytokine  or  perforin  secretion.  In  the  last
phase,  the  destroyed  myocytes  are  replaced  by  diffuse  ﬁbro-
sis,  leading  to  dilated  ventricles  and  cardiac  failure.8
Myocarditis,  as  well  as  other  heart  complications  of  EBV
like  pericarditis,  might  even  precede  clinical  IM,  hindering
the  diagnosis.7
AtherosclerosisThe  role  of  EBV  in  the  pathogenesis  of  atherosclerosis  is
based  on  ﬁndings  suggesting  that  EBV  DNA  is  commonly  found
in  atheromatous  plaques.  However,  EBV  DNA  presence  in
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theroma  ranges  from  12%  to  80%,  thus  these  ﬁndings  are
uestionable.9
This  complication  regards  only  adults,  and  the  possible
echanism  is  based  on  EBV-encoded  enzyme  deoxyuridine
riphosphate  nucleotidohydrolase  (dUTPase).  dUTPase  has
een  shown  to  induce  the  production  of  pro-inﬂammatory
ytokines  such  as  interleukin-6  (IL-6)  and  endothelial  cell
xpression  of  intercellular  adhesion  molecule-1  (ICAM-1).
motional  and  psychosocial  stress  is  believed  to  deregu-
ate  immune  repression  of  the  virus,  allowing  its  replication
nd  the  production  of  dUTPase.  This  mechanism  provides
n  explanation  for  the  connection  between  stress,  EBV,  and
oronary  artery  events.10 EBV-induced  gene  3  (Ebi3)  is  also
mplicated  in  atherosclerosis.11
ematological complications
hrombocytopenia
ild  thrombocytopenia  occurs  in  25--50%  of  uncomplicated
ases  during  the  acute  phase  of  the  disease.  An  occa-
ional  patient  may  have  thrombocytopenia  for  8  weeks  or
ore.  In  contrast,  severe  thrombocytopenia  (platelet  count
20  ×  109/L)  is  rare,  with  38  reported  cases.  Twenty-eight  of
hese  patients  were  younger  than  21  years  old.  Two  of  these
atients  died  of  complications  from  thrombocytopenia  and
emorrhage.12 Although  severe  EBV-associated  thrombocy-
openia  is  rare,  it  can  have  life-threatening  consequences.
his  complication  should  be  considered  in  any  patient  with
cute  EBV  infection  and  evidence  of  mucosal  or  dermal
leeding.13
It  has  been  proposed  that  the  pathophysiology  of  throm-
ocytopenia  includes  the  presence  of  a  platelet-destroying
gglutinin  produced  in  response  to  a viral  agent--platelet
ond.  Other  possible  mechanisms  include  vascular  damage
ue  to  the  infectious  agents,  and  hypersplenism  or  anti-
ody  formation  in  the  spleen  and  the  reticuloendothelial
ystem.12
plastic  anemia
plastic  anemia  following  primary  EBV  infection  or  in  asso-
iation  with  reactivation  of  EBV  infection  has  been  reported
n  24  cases  in  the  literature.  Seventeen  of  these  cases  were
hildren  under  18  years  old.  However,  it  is  likely  that  some
ases  of  aplastic  anemia  characterized  as  idiopathic  are,  in
act,  triggered  by  an  EBV  infection,  since  in  young  children
BV  infection  presents  with  atypical  symptoms.14
EBV  infected  B-cells  may  provoke  oligoclonal  expan-
ion  of  suppressor  T-cells  (CD8+,  CD28−), which  prevent
utologous  marrow  hematopoietic  cells  development.  EBV-
ssociated  and  idiopathic  aplastic  anemia  have  similar
rognosis.14
granulocytosisild  neutropenia  is  a  common  manifestation  in  IM  during
he  ﬁrst  weeks  of  illness,  but  agranulocytosis  or  severe  neu-
ropenia  after  IM  is  very  rare,  with  only  29  cases  reported.15
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The  pathogenesis  of  agranulocytosis  after  IM  may  involve
ecreased  production  or  maturation  of  myeloid  cells  in  the
arrow,  as  a  result  of  the  direct  effect  of  EBV  or  antibody-
ediated  peripheral  destruction  of  myeloid  cells.  The
ypothesis  of  maturation  arrest  of  myeloid  cells  has  been
uggested  because  mature  myeloid  cells  disappear  in  the
atient’s  bone  marrow.  Anti-human  neutrophil  antigen-1a
anti-HNA-1a)  and  anti-HNA-1b  antibodies  are  both  associ-
ted  with  the  pathophysiology  in  agranulocytosis  after  IM,
lthough  it  is  unknown  whether  anti-neutrophil  antibodies
re  produced  in  EBV-infected  B  cells.15
ymphohistiocytosis
emophagocytic  syndrome  or  hemophagocytic  lymphohis-
iocytosis  (HLH)  is  a  rare,  life-threatening  disease  caused  by
 dysfunction  of  cytotoxic  T  cells  and  NK  cells.16 Incidence
f  HLH  is  estimated  at  one  case  per  800,000  people,  half
f  which  are  associated  with  EBV.  EBV-associated  HLH  has
een  observed  in  infants,  children,  and  adults,  but  80%  of
he  cases  occur  in  children  of  1--14  years  of  age.  HPS  can  be
ither  primary,  i.e., due  to  an  underlying  genetic  defect;
r  secondary,  associated  with  malignancies,  autoimmune
iseases  (macrophage  activation  syndrome),  or  infections.
nfectious  triggers  are  mainly  viruses  of  the  herpes  group,
ith  EBV  being  the  most  common.17
Possible  mechanism  includes  T  cell/NK  cell  deregula-
ion,  which  leads  to  increased  cytokine  release,  resulting
n  activation  of  histiocytes  followed  by  hemophagocy-
osis.  Histiocytic  inﬁltration  of  the  reticuloendothelial
ystem  causes  hepatomegaly,  splenomegaly,  lymphadeno-
athy,  and  pancytopenia,  eventually  leading  to  multiple
rgan  dysfunctions.16
enitourinary system complications
enal  dysfunction
BV  infection’s  renal  involvement  varies  from  microscopic
ematuria  and  mild  proteinuria  to  acute  renal  failure.18
enal  dysfunction  in  IM  is  infrequent,  mostly  self-limited,
nd  is  rarely  associated  with  failure  of  renal  function.  Evi-
ence  of  mild  renal  involvement  may  be  present  up  to  16%
n  patients  with  IM,  but  severe  renal  failure  is  rare.19
Hematuria  or  proteinuria  can  be  found  in  2%  and  18%  of
M  cases  respectively,  whereas  azotemia  has  been  reported
n  only  eight  cases.  Interstitial  nephritis  is  the  most  com-
on  histologic  abnormality.  EBV  is  believed  to  play  a  vital
ole  in  the  pathogenesis  of  IgA  nephropathy.  Occasional  case
eports  of  nephrotic  syndrome,  hemolytic  uremic  syndrome,
epatorenal  syndrome,  and  rhabdomyolysis  in  patients  with
M  have  also  appeared.18 Acute  renal  failure,  although  less
ommon,  has  been  associated  primarily  with  rhabdomyolysis
nd  interstitial  nephritis.19
Finally,  membranous  nephropathy  is  a  result  of  a
rolonged  systemic  viral  proliferation  and  persistent  anti-
enemia  in  IM  patients  who  lack  a  fully  competent  immune
ystem,  thus  leading  to  immune  complex  deposition  in  the
idney.19
The  possibility  of  IM  should  be  considered  when  patients
resent  acute  renal  failure,  particularly  if  other  features
c
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uch  as  fever,  hemolytic  anemia,  hepatitis,  or  thrombocy-
openia  are  present.18
enital  ulcers
enital  ulceration  is  an  uncommon  manifestation  of  primary
BV  infection.  Identiﬁed  by  the  Austrian  dermatologist  Lip-
chütz  as  an  acute  disease  with  fever,  genital  ulceration,
nd  lymphadenomegaly  in  young  women  in  1913  and  called
ipschütz’s  ulcer,  today  it  is  attributed  to  EBV  infection.20
orty-one  cases  have  been  reported,  with  the  vast  majority
eing  females.21--23
Patients  develop  one  or  more  large  ulcers  with  diame-
er  between  0.3  and  4  cm.24 The  EBV-associated  ulcers  are
ften  quite  deep  and  necrotic,  with  irregular  edges,  and  may
ause  pain  and  urinary  symptoms.  The  mean  healing  time  is
8  days.20
There  have  been  three  hypotheses  suggested  for  the
athogenesis  of  EBV  genital  ulcers.  The  ﬁrst  hypothesis
ncludes  type  III  hypersensitivity  reaction  to  immune  com-
lexes  produced  in  the  acute  phase  of  EBV  infection.  EBV
enital  ulcers  could  also  result  from  cytolysis  due  to  EBV
eplication  in  vulvar  keratinocytes,  along  with  the  inﬂam-
atory  response  to  viral  agents.  Finally,  these  ulcers  might
epresent  a  type  of  aphthosis.23
EBV  is  also  present  elsewhere  in  the  female  genital  tract;
owever,  its  pathogenic  role  in  the  cervix,  uterus,  fallopian
ubes,  and  ovaries  is  poorly  understood.22
astrointestinal complications
epatitis
holestatic  hepatitis  with  mild  liver  dysfunction  has  been
eported  in  more  than  90%  of  patients  with  primary
BV  infection,  but  severe  liver  dysfunction  or  gallbladder
nvolvement  is  rare.25 Primary  EBV  infection  can  cause  a
ild  self-limited  hepatitis,  which  typically  resolves  with-
ut  clinical  importance;  jaundice  can  be  seen  in  5--10%  of
ases.  Liver  function  abnormalities  most  often  occur  during
he  second  week  of  illness  and  resolve  within  2--6  weeks.25
cute  acalculous  cholecystitis
leven  cases  of  acute  acalculous  cholecystitis  (AAC)  have
een  reported  during  the  course  of  primary  EBV  infection,
0  of  which  were  in  children  or  young  adults.24
The  main  cause  of  AAC  is  gallbladder  stasis  and  stag-
ation  of  bile.  Increased  bile  viscosity,  gallbladder  wall
schemia,  and  proinﬂammatory  mediators  like  eicosanoid
ave  also  been  implicated  in  the  pathogenesis.  Gallblad-
er  wall  thickening  and  sludge  formation  may  occur  during
he  course  of  viral  hepatitis.  Hydrops  of  the  gallbladder  may
ccasionally  develop  during  IM.  Whether  the  increased  thick-
ess  of  the  gallbladder  wall  results  from  direct  invasion  of
he  gallbladder  mucosa  by  EBV  or  whether  EBV-associated
holestasis  causes  the  gallbladder  wall  irritation  or  both  is
ot  established.24
Recovery  in  all  reported  cases  was  excellent  without  any
urgical  treatment.  Clinicians  should  be  aware  that  AAC  may
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complicate  IM,  thus  avoiding  unnecessary  invasive  surgery
and  antibiotic  therapy.24
Acute  liver  failure
Acute  EBV  infection  is  a  rare  cause  of  acute  liver  failure
(ALF)  in  young  adults,  but  the  available  data  are  insufﬁcient
and  there  are  not  reports  for  children.  As  demonstrated  by
an  1887  patient  cohort  study,  EBV  is  responsible  for  only
0.21%  of  ALF  cases.  Most  cases  occur  post-transplantation
or  are  associated  with  immunodeﬁciency  syndromes.26 Since
EBV  is  a  ubiquitous  virus  and  lacks  a  speciﬁc  treatment,
there  is  a  signiﬁcant  risk  for  children  who  are  EBV  nega-
tive  before  liver  transplantation  to  be  infected  by  an  adult
EBV  positive  liver.  Rising  EBV  titers  should  be  approached
with  reduction  of  immunosuppression.27 It  is  questionable  if
the  pathophysiology  of  EBV-related  ALF  is  due  to  a  gener-
alized  host  immune  response  to  EBV  antigens  or  increased
viral  replication.26
Splenic  rupture
Splenomegaly  is  a  common  complication  of  IM  and  of  other
infectious  conditions.  It  is  frequently  self-limited.  Sponta-
neous  splenic  rapture,  however,  is  a  rare  manifestation  of
IM,  estimated  at  0.1--0.5%  of  IM  cases.28 Most  of  reported
splenic  ruptures  occurred  within  3  weeks  after  IM  diagnosis,
but  rupture  appears  to  occur  even  after  7  weeks.17
EBV  infection  is  believed  to  damage  the  splenic  architec-
ture  by  invading  the  spleen  with  lymphocytes  and  atypical
lymphoid  cells.  This  inﬁltration  weakens  the  ﬁbrous  support
system  of  the  spleen  and  the  splenic  capsule  becomes  thin-
ner,  promoting  the  rupture.  The  rupture  may  occur  following
a  minor  trauma  or  spontaneously.  The  spontaneous  rupture
is  hypothesized  to  be  a  result  of  either  an  acute  increase
in  portal  venous  pressure  caused  by  Valsalva  maneuver  or
the  compression  of  the  enlarged  spleen  by  the  contracted
diaphragm  or  the  abdominal  wall.28
Most  cases  report  full  resolution  of  hematoma  from  4
weeks  up  to  1  year.  There  is  evidence  supporting  that  the
spleen  can  retain  full  function  while  maintaining  a  low
risk  for  repeat  rupture  even  after  parenchymal  disruption.
Thus,  non-operative  management  of  splenic  rupture  during
IM,  in  a  stable  trauma  patient,  appears  to  be  the  treat-
ment  of  choice,  when  also  considering  the  risks  following
a  splenectomy.28
Since  splenic  rupture  is  more  frequent  within  3  weeks
of  the  infection  onset,  it  is  suggested  that  patients  should
refrain  from  sports  for  a  minimum  3  weeks  or  once  clinical
symptoms  and  ﬁndings  are  resolved.17
Neurological complications
Facial  nerve  palsy
There  have  been  only  14  cases  of  EBV-associated  facial
nerve  palsy  (FNP).  Of  these,  36%  of  the  cases  were  bilat-
eral,  although  bilateral  FNP  among  FNP  patients  ranges  from
0.3%  to  2%.  Otomastoiditis  caused  by  EBV  may  transmit  the
infection  to  the  facial  nerve  leading  to  this  type  of  FNP,
s
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ince  it  was  recognized  in  two  of  these  cases.  Another  possi-
le  explanation  is  the  direct  viral  invasion  or  immunological
esponse  to  EBV  by  the  central  nervous  system.  The  mean
ge  of  these  patients  compared  to  non-EBV-associated  FNP
atients  was  much  lower.  This  is  associated  with  increased
ncidence  of  EBV  infection  during  childhood.29
EBV  infection  should  be  suspected  in  patients  with  FNP,
specially  when  it  is  bilateral,  even  when  systemic  manifes-
ations  of  EBV  infection  are  absent.  These  patients  do  not
equire  any  special  treatment.30
uillain--Barre  syndrome
here  have  been  several  case  reports  since  1947  reporting
BV  infection  to  precede  Guillain--Barre  syndrome  (GBS).  It
as  also  been  reported  that  EBV  is  responsible  for  10%  of
BS  cases.  However,  the  criteria  used  in  these  reports  are
uestionable,  since  EBV  is  ubiquitous.31 The  excess  risk  of
BS  in  the  2  months  following  EBV  infection  is  believed  to
e  20-fold.32
ncephalitis
he  incidence  of  EBV  encephalitis  is  less  than  0.5%,  but  it
ay  be  increased  to  7.3%  among  children  who  are  hospital-
zed  with  IM.33 Fatalities  occur  in  0.1--1%  of  these  cases.2 EBV
ncephalitis  commonly  presents  with  confusion,  decreased
evel  of  consciousness,  fever,  and  epileptic  seizures.  The
anifestations  of  EBV  encephalitis  may  exist  before,  dur-
ng,  or  even  after  the  symptoms  of  IM.34 However,  most
atients  with  EBV  encephalitis  do  not  show  typical  symp-
oms  of  IM;  therefore,  EBV  should  be  considered  a  possible
ause  of  acute  childhood  encephalitis,  regardless  the  pres-
nce  of  IM  symptoms.33 EBV  encephalitis  prognosis  may  vary
rom  complete  recovery  to  death.34
EBV  encephalitis  involves  a  wide  diversity  of  locations  in
entral  nervous  system,  with  the  cerebellum,  cerebral  hemi-
phere,  and  basal  ganglia  as  the  most  frequent.  Patients  with
solated  brain  stem  involvement  are  characterized  by  the
ighest  mortality,  whereas  patients  with  thalamic  involve-
ent  were  recognized  with  the  most  consequences.  Isolated
ortical  involvement  and  involvement  of  spinal  cord  were
ssociated  with  excellent  prognosis.34
The  pathogenesis  of  EBV-induced  neurologic  injury  has
ot  been  elucidated,  although  it  is  suggested  that  immuno-
ogic  mechanisms  are  mostly  responsible  rather  than
ncreased  viral  replication.33
lice  in  Wonderland  syndrome
lice  in  Wonderland  syndrome  (AIWS)  is  characterized  by
etamorphopsia,  the  self-reported  presence  of  somatosen-
ory  alteration,  such  as  distortion  in  the  perception  of  size
nd  shape  of  a  patient’s  body  and  illusions  of  changes  in  the
ize,  distance,  form,  even  colors  or  spatial  relationships  of
bjects.35 The  illusions  and  hallucinations  are  similar  to  the
trange  incidents  that  Alice  experienced  in  Lewis  Carroll’s
‘Alice’s  Adventures  in  Wonderland.’’36
AIWS  is  primarily  described  in  patients  with  epilepsy  or
igraine  and  drug  abusers,  and  has  rarely  been  described  in
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ssociation  with  EBV  and  other  viral  infections.35 Four  cases
ith  AIWS  secondary  to  IM  have  been  reported,  including
wo  adolescents,  a  9½ year-old  boy  and  a  7-year-old  girl
ith  EBV  encephalopathy.36,37
Metamorphopsia  may  precede  onset  or  follow  the  resolu-
ion  of  all  clinical  signs  and  symptoms.  The  duration  of  the
isual  illusion  ranges  between  2  weeks  and  7  months,  but
ith  complete  recovery  in  all  described  cases.35
AIWS  diagnosis  may  be  complicated  if  the  visual  distur-
ances  precede  the  classic  symptoms  of  IM  or  if  IM  follows
 subclinical  course.38 Therefore,  patients  compatible  with
IWS  symptoms  should  be  suspected  for  EBV  infection.35
sychiatric complications
sychotic  episodes
everal  studies  suggest  a  link  between  early-life  infection
nd  adult  schizophrenia  and  increased  prevalence  of  EBV  in
he  latter.  EBV  is  a  known  neurotropic  infectious  agent,  since
t  is  a  member  of  the  Herpesviridae  family.  The  human  brain
ontinues  to  develop  through  childhood  and  early  adulthood,
hus  infection  during  this  period,  especially  with  neurotrop-
ng  agents,  could  potentially  increase  the  risk  of  neurological
bnormalities.39
Possible  pathophysiological  mechanisms  include  inﬂam-
atory  cytokines  affecting  the  brain  after  the  activation
f  the  innate  immune  system.  Early-life  infection  harms
icroglia,  distorting  neuronal  survival  and  functioning.  It  is
lso  believed  that  there  is  a  connection  between  genetic
sychosis  background  and  vulnerability  to  infection.39
atigue
M  is  a  speciﬁc  and  strong  risk  factor  for  the  development  of
atigue,  subsequently.  However,  it  is  possible  that  doctors
re  biased,  thus  overestimating  the  prevalence  of  post-IM
atigue  compared  to  that  of  other  viral  infections.  Con-
ersely,  doctors  may  not  record  fatigue  after  IM,  considering
t  as  an  expected  sequel  of  any  viral  infection.  Fatigue  is  a
ubjective  symptom  and  so  is  difﬁcult  to  calculate  as  a  fea-
ure  of  the  illness.  Possible  risk  markers  for  fatigue  after
M  are  female  sex,  premorbid  mood  disorder,  lack  of  physi-
al  ﬁtness,  inactivity,  and  illness  perception.  These  markers
ay  be  used  to  target  prevention  strategies  and  explore
tiological  mechanisms.40
epression
he  association  between  infectious  agents  and  depression
as  been  controversial.  Early  clinical  studies  supported  an
ssociation  of  raised  antibody  titers  against  HSV  and  EBV
ith  depression.  However,  opposing  results  have  also  been
eported  that  reveal  no  signiﬁcant  association  between
ntibodies  to  HSV,  inﬂuenza,  or  neurotropic  viruses  with
epression.  Findings  suggest  that  smaller  sample-sized  stud-
es  tend  to  produce  negative  results,  and  identifying  a
igniﬁcant  association  between  EBV  infection  and  depression
ay  require  a  sufﬁciently  large  sample  size.41
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utoimmunity
he  major  environmental  risk  factors  for  systemic  autoim-
une  diseases  are  infections.1 EBV  has  been  suggested  to
e  associated  with  autoimmune  diseases,  such  as  rheuma-
oid  arthritis  (RA),  systemic  lupus  erythematosus,  multiple
clerosis  (MS),  inﬂammatory  bowel  diseases,  autoimmune
hyroiditis,  insulin-dependent  diabetes  mellitus,  Sjögren’s
yndrome,  autoimmune  liver  diseases,  systemic  sclerosis,
nd  myasthenia  gravis.42
One  of  the  main  mechanisms  of  how  infections  may
ause  autoimmunity  is  molecular  mimicry.  It  is  believed  that
equence  or  structural  similarities  between  microbial  and
elf-antigens  cross-react  with  B-cells,  T-cells,  and  antibod-
es.  Such  examples  are  anti-citrullinated  protein  antibodies
n  RA  and  autoantibodies  against  B-crystallin  in  MS.42
An  additional  theory  is  referred  to  as  bystander  acti-
ation.  In  this  case,  the  inﬂammatory  background  of  an
nfection  promotes  activation  or  expansion  of  previously
ctivated,  autoreactive  lymphocytes.  Activation  and  expan-
ion  of  autoreactive  T-cells  are  known  to  occur  due  to  the
irus-induced  severe  local  inﬂammation  and  intense  local
ytokine  production.1 EBV  proteins  involved  in  immune  eva-
ion  and  suppression  of  apoptosis  of  transformed  infected
ymphocytes  are  likely  to  result  in  loss  of  tolerance  and
evelopment  of  autoimmunity.42
It  has  been  suggested  that  raised  serum  titers  of  antibod-
es  against  EBV  in  autoimmune  diseases  could  be  the  result
f  polyspeciﬁc  B-cell  activation.  In  response  to  polyclonal
timuli,  memory  B-cells  proliferate  and  differentiate  into
lasma  cells;  this  may  depict  a  natural  mechanism  for  the
erpetuation  of  a lifelong  serological  immunity.42
Another  hypothesis  is  the  accumulation  of  T-cells,  due
o  EBV  frequent  reactivation.  EBV  speciﬁc  CD8+  T-cells
re  enriched  in  or  near  the  diseased  organs  of  patients
ith  RA  and  MS,  and  they  also  accumulate  in  synovial
uid  from  patients  with  psoriatic  arthritis,  osteoarthritis,
nd  Reiter’s  syndrome.  This  could  reﬂect  a  local  immune
esponse  against  EBV  in  the  diseased  organs.42
After  many  years  of  viral,  immunological,  and  epidemio-
ogical  research,  it  is  still  debated  whether  EBV  is  a causative
gent  of  these  autoimmune  entities.42
llergies
ypersensitivity  to  mosquito  bites
his  disease  has  appeared  mostly  in  Japanese  children.  More
han  50  cases  of  hypersensitivity  to  mosquito  bites  (HMB)
ave  been  reported  in  Japan,  and  there  are  several  reports
f  cases  in  Taiwan  and  Mexico.  HMB  is  identiﬁed  by  intense
ocal  skin  symptoms,  which  comprise  bulla,  erythema,  and
lceration  or  scarring,  and  systemic  symptoms  such  as  lym-
hadenopathy,  high  fever,  and  hepatosplenomegaly.43
CD4+  T  cells  from  HMB  patients  react  to  speciﬁc  mosquito
alivary  gland  extracts.  These  T  cells  induce  the  reactivation
f  latent  EBV  infection  in  NK  cells.  EBV-carrying  NK  cells  in
MB  patients  overexpress  surface  Fas  ligand  (Fas  L)  and  the
nhanced  Fas  L  might  be  related  to  tissue  damage,  such  as
xcessive  skin  lesions  at  mosquito  bite  sites  and  liver  dys-
unction.  It  has  been  suggested  that  these  patients  show
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increased  expression  of  viral  oncogene  LMP1  in  EBV-infected
NK  cells,  and  the  mosquito  antigen  also  increases  the
expression  and  induces  NK  cell  proliferation.  LMP1  activates
various  signaling  pathways  during  transformation,  including
PI3  kinase,  Rac,  NF-kB,  and  reactive  oxygen  signaling.43
Epidemiological  observations  suggest  the  possibility  of
endemic  development  of  HMB,  as  a  result  of  the  patient’s
genetic  background  or  the  impact  of  multiple  environmental
factors.43
Neoplasms
It  is  estimated  that  each  year  EBV  is  responsible  for  84,000
cases  of  gastric  carcinomas,  78,000  cases  of  nasopharyn-
geal  carcinoma,  and  28,000  cases  of  Hodgkin  lymphoma.  It
is  notable  that  the  risk  of  EBV-positive  Hodgkin  lymphoma
culminates  at  4  years  after  IM,  while  it  decreases  to  nor-
mal  after  10  years.  Each  year  there  are  over  6000  cases
of  EBV  associated  Burkitt  lymphoma  (BL)  in  less  developed
countries.  The  prevalence  of  BL  in  central  Africa  is  20  cases
per  100,000  in  children  between  the  ages  of  5  and  9  years.44
EBV  is  also  associated  with  malignancies  in  immuno-
compromised  patients.  EBV  lymphoma,  for  example,
is  the  second  most  common  malignancy  developing
after  organ  transplantation,  because  of  the  respective
immunodeﬁciency.44
The  most  relevant  children’s  neoplasm  derived  from  EBV
is  Burkitt  lymphoma.45 Denis  Burkitt  observed  a  form  of  BL,
endemic  BL,  which  is  most  commonly  seen  in  regions  of
sub-Saharan  Africa.  Regions  of  endemic  BL  have  a  very  high
frequency  of  disease,  roughly  5--10  cases  per  100,000  chil-
dren.  Viral  genomes  can  be  found  in  nearly  100%  of  endemic
BL  tumors.46
BL  occurs  worldwide  at  a  much  lower  incidence  in  a
form  known  as  sporadic  BL,  which  is  also  seen  primarily  in
children,  but  has  a  lower  association  with  EBV  infection.
Sporadic  BL  varies  from  15%  to  85%  of  viral  tumors.46
The  contribution  of  EBV  to  the  pathogenesis  of  BL  is
similarly  enigmatic.  EBV  leads  to  the  development  of  trans-
formed  but  not  malignant  lymphoblastoid  cell  lines  (LCLs),
by  activating  the  proliferation  of  B  cells.  LCLs  are  respon-
sible  for  the  expression  of  numerous  EBV-encoded  latency
proteins,  many  of  which  modulate  key  regulatory  pathways
such  as  PI3K  and  NF-kB,  which  have  been  solidly  linked  to
cancer.  In  the  absence  of  functional  T  cells  or  during  continu-
ous  antigen  presence,  EBV-induced  LCLs  grow  unhindered.47
EBV  also  inhibits  the  apoptosis  of  premalignant  tumor  cells,
allowing  transforming  events  to  occur.1 The  ﬁnal  steps  of  the
oncogenic  pathway  are  the  translocations  in  MYC  and  TCF-
3  genes.  These  are  the  most  common  mutations  caused  by
EBV,  which  lead  to  the  production  of  oncogenic  transcription
factors  in  BL.47
X-linked lymphoproliferative disease
Primary  EBV  infection  in  boys  with  X-linked  lymphoprolife-
rative  disease  (XLPD)  leads  to  fulminant,  often  even  fatal
disease.  In  addition,  the  condition  predisposes  to  consider-
ably  elevated  incidence  of  lymphomas.48
Mutation  or  deletion  of  the  SH2D1A  gene  causes  lack
of  functional  signaling  lymphocytic  activation  molecule
C
T119
SLAM)-associated  protein  (SAP),  which  regulates  T-cell
poptosis.  The  lack  of  SAP  results  in  uncontrolled  pro-
iferation  of  CD8+  T-lymphocytes  leading  to  XLPD.  T-cell
poptosis,  which  is  also  inefﬁcient  in  the  IM  mostly  due  to  the
pstein--Barr  virus  nuclear  antigen  anti-apoptotic  function,
nhances  the  effects  of  SAP  absence.48
iscussion
BV  infects  virtually  everyone  by  adulthood,  and  a  lifelong
atency  is  maintained.  It  infects  children  silently,  whereas
he  majority  of  adolescents  develop  IM  when  infected.17 On
are  occasions  the  symptoms  of  IM  may  persist  in  a chronic  or
ecurrent  form,  and  fatal  IM  occurs  rarely.  Depending  on  the
ype  and  degree  of  immune  deﬁciency  and  the  time  the  EBV
nfection  occurs  in  the  life  cycle,  various  atypical  outcomes
an  occur.1
These  manifestations  may  be  acute,  such  as  genital  ulcers
nd  acute  dacryocystitis,4,20 or  delayed,  such  as  autoimmu-
ity  and  atherosclerosis.10,42 Some  of  them  may  be  relatively
enign  like  fatigue,  allergies,  and  FNP13,30,43 and  others
ay  be  life-threatening,  like  splenic  rupture  and  ALF.17
he  remaining  EBV  complications  include  myocarditis,  renal
ysfunction,  hepatitis,  and  AAC,8,19,24,25 as  well  as  sev-
ral  hematological,  neurological,  and  respiratory  entities.16
lthough  these  manifestations  are  quite  rare,  physicians  and
specially  pediatricians  should  be  aware  of  such  cases  in
rder  to  avoid  unnecessary  treatment  and  procedures,  since
M  would  be  easily  treated  only  with  supportive  care.17,24
hen  similar  signs  and  symptoms  to  the  aforementioned
re  present,  the  differential  diagnosis  should  include  EBV
s  a  causative  agent.  The  patient’s  history  is  of  great
mportance  and  may  provide  the  ﬁrst  indications  for  the
ppropriate  diagnosis.  Individualization  and  optimization  of
he  patient’s  follow-up  would  also  aid  in  preventing  and
reating  possible  complications.3 In  other  words,  knowledge
f  these  scenarios  would  be  beneﬁcial  for  both  the  child’s
ealth  and  the  treatment  cost,  hence  improving  medical
ractice.
It  is  notable  that  there  are  many  open  questions
egarding  the  mentioned  manifestations  and  further  stud-
es  are  needed  to  elucidate  the  role  of  the  immunological
echanism  of  EBV  on  various  target  organs.42 The  full  under-
tanding  of  these  mechanisms  and  the  correlation  between
BV  and  the  pathological  entities  will  assist  in  the  treatment
nd  prevention  of  severe  morbidity.
Nonetheless,  the  immune  system  is  critical  in  preven-
ing  the  progression  of  EBV  disease,  since  the  immunological
tatus  of  the  patient  plays  a  crucial  role  in  the  subsequent
evelopment  of  pathologies.1 As  life  expectancy  increases
nd  as  more  manipulations  of  the  immune  system  are
chieved,  more  unusual  manifestations  of  EBV  infection
ill  appear,  which  will  be  a  diagnostic  challenge  in  the
uture.onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
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